X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ANX007 is a fragment antigen-binding (Fab) antibody designed as a first-in-kind therapeutic to selectively inhibit C1q, the initiating molecule of the classical complement pathway. It is under phase 2 clinical development for the treatment of Geographic Atrophy.
Lead Product(s): ANX007
Therapeutic Area: Ophthalmology Product Name: ANX007
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2023
Details:
The net proceeds will be used to advance the global registrational program for ANX007, a fragment antigen-binding antibody designed as a first-in-kind therapeutic to selectively inhibit C1q and a key driver of neurodegeneration, in geographic atrophy.
Lead Product(s): ANX007
Therapeutic Area: Ophthalmology Product Name: ANX007
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 20, 2023
Details:
ANX1502 is a classical complement pathway inhibitor, small molecule drug candidate, which is currently being evaluated for the treatment of patients with cold agglutinin disease.
Lead Product(s): ANX1502
Therapeutic Area: Immunology Product Name: ANX1502
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2023
Details:
ANX007 is a fragment antigen-binding (fab) antibody designed as a first-in-kind therapeutic to selectively inhibit C1q, the initiating molecule of the classical complement pathway, and a key driver of neurodegeneration.
Lead Product(s): ANX007
Therapeutic Area: Ophthalmology Product Name: ANX007
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Details:
ANX005 is a a monoclonal antibody (mAb) designed to fully block C1q and the entire classical complement pathway with the aim of preserving functioning synapses to slow or halt neurodegeneration. It is beig evaluated for GBS autoimmune disoder.
Lead Product(s): ANX005
Therapeutic Area: Rare Diseases and Disorders Product Name: ANX005
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
Details:
ANX007 represents the first complement therapeutic candidate to preserve visual acuity, demonstrating a statistically significant reduction of vision loss in both foveal and non-foveal patients at 12 months.
Lead Product(s): ANX007
Therapeutic Area: Ophthalmology Product Name: ANX007
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2023
Details:
ANX005 is a a monoclonal antibody (mAb) designed to fully block C1q and the entire classical complement pathway with the aim of preserving functioning synapses to slow or halt neurodegeneration. It is beig evaluated for GBS autoimmune disoder.
Lead Product(s): ANX005
Therapeutic Area: Rare Diseases and Disorders Product Name: ANX005
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2023
Details:
Interim data show that treatment with ANX005 has led to full target engagement of C1q in both serum and CSF through the dosing period in patients who were evaluable as of the cutoff date of October 17, 2021 (n=13).
Lead Product(s): ANX005
Therapeutic Area: Immunology Product Name: ANX005
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
ANX007 is an antigen-binding fragment (Fab) formulated for intravitreal administration that is designed for localized inhibition of C1q and the classical complement pathway in neurodegenerative diseases of the eye.
Lead Product(s): ANX007
Therapeutic Area: Ophthalmology Product Name: ANX007
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2022
Details:
The company’s pipeline includes three clinical-stage drug candidates, ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration), as well as a robust early-stage pipeline of preclinical and discovery stage programs.
Lead Product(s): ANX005
Therapeutic Area: Immunology Product Name: ANX005
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
